Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Rang în acțiuni #36446
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Preț acțiune
$1.73
Ultima sincronizare: 2025-06-17
Capitalizare de piață
$2.55M
Schimbare (1 zi)
-0.29%
Schimbare (1 an)
-79.71%
Țară
US
Tranzacționează Eiger BioPharmaceuticals, Inc. (EIGR)

Categorie

Healthcare
Venituri pentru Eiger BioPharmaceuticals, Inc. (EIGR)
Venituri în Dec 2023 TTM: $15.77M
Conform celor mai recente rapoarte financiare ale Eiger BioPharmaceuticals, Inc., venitul actual al companiei (TTM) este $15.77M. În anul 2022, compania a avut un venit de $13.48M o creștere față de venitul din anul 2021, care a fost de $12.14M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Eiger BioPharmaceuticals, Inc. din 2016 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $15.77M 0.00%
2023 $15.77M 16.98%
2022 $13.48M 11.05%
2021 $12.14M 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 79,937.41%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 14,025.40%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 99,718.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 38,074.65%
NL